U2Bio Co., Ltd.
U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.
U2Bio Co., Ltd. (221800) - Net Assets
Latest net assets as of March 2025: ₩34.10 Billion KRW
Based on the latest financial reports, U2Bio Co., Ltd. (221800) has net assets worth ₩34.10 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩44.34 Billion) and total liabilities (₩10.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩34.10 Billion |
| % of Total Assets | 76.9% |
| Annual Growth Rate | 0.86% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.82 |
U2Bio Co., Ltd. - Net Assets Trend (2022–2024)
This chart illustrates how U2Bio Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for U2Bio Co., Ltd. (2022–2024)
The table below shows the annual net assets of U2Bio Co., Ltd. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩34.43 Billion | -9.38% |
| 2023-12-31 | ₩37.99 Billion | +12.25% |
| 2022-12-31 | ₩33.84 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to U2Bio Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩14.86 Billion | 43.16% |
| Common Stock | ₩5.64 Billion | 16.39% |
| Other Components | ₩13.93 Billion | 40.45% |
| Total Equity | ₩34.43 Billion | 100.00% |
U2Bio Co., Ltd. Competitors by Market Cap
The table below lists competitors of U2Bio Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JTL Industries Ltd
NSE:JTLIND
|
$84.15 Million |
|
Metropolitan Kentjana Tbk
JK:MKPI
|
$84.16 Million |
|
Asian Granito India Limited
NSE:ASIANTILES
|
$84.16 Million |
|
Banque Nationale de Belgique S.A.
LSE:0DT1
|
$84.17 Million |
|
Dimeco Inc
OTCQX:DIMC
|
$84.10 Million |
|
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
|
$84.04 Million |
|
Semperit AG Holding
LSE:0G29
|
$84.04 Million |
|
Simplex Infrastructures Limited
NSE:SIMPLEXINF
|
$84.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in U2Bio Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,991,410,210 to 34,427,465,470, a change of -3,563,944,740 (-9.4%).
- Net loss of 2,840,499,100 reduced equity.
- Dividend payments of 338,615,880 reduced retained earnings.
- Other factors decreased equity by 384,829,760.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.84 Billion | -8.25% |
| Dividends Paid | ₩338.62 Million | -0.98% |
| Other Changes | ₩-384.83 Million | -1.12% |
| Total Change | ₩- | -9.38% |
Book Value vs Market Value Analysis
This analysis compares U2Bio Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.92x to 7.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩3350.23 | ₩23200.00 | x |
| 2023-12-31 | ₩3365.88 | ₩23200.00 | x |
| 2024-12-31 | ₩3050.13 | ₩23200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently U2Bio Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.34%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.31x
- Recent ROE (-8.25%) is below the historical average (10.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 38.88% | 19.07% | 1.35x | 1.51x | ₩9.78 Billion |
| 2023 | 1.70% | 2.10% | 0.63x | 1.30x | ₩-3.15 Billion |
| 2024 | -8.25% | -11.34% | 0.56x | 1.31x | ₩-6.28 Billion |
Industry Comparison
This section compares U2Bio Co., Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $85,945,398,630
- Average return on equity (ROE) among peers: -19.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| U2Bio Co., Ltd. (221800) | ₩34.10 Billion | 38.88% | 0.30x | $84.13 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |